ArticleRegenerative medicine2024
Risk-based pricing models and the role they might play in patients' access to new stem cell therapies.
Klaus Hoeyer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it